Managing HBV and HCV Infection Pre- and Post-liver Transplant

Managing HBV and HCV Infection Pre- and Post-liver Transplant

Hepatitis B and C are common causes of end-stage liver disease and etiologies of liver transplantation. It is important to prevent recurrence in cases of hepatitis B. Nucleos(t)ide analogs are the mainstay of HBV treatment before (in patients with decompensated cirrhosis) and after liver transplanta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical and experimental hepatology 2024-03, Vol.14 (2), p.101287-101287, Article 101287
Hauptverfasser: Kumar, Naveen, Choudhary, Narendra S.
Format: Artikel
Sprache:eng
Schlagworte:
decompensated cirrhosis recurrence
delisting
direct-acting antivirals
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 101287
container_issue 2
container_start_page 101287
container_title Journal of clinical and experimental hepatology
container_volume 14
creator Kumar, Naveen
Choudhary, Narendra S.
description Hepatitis B and C are common causes of end-stage liver disease and etiologies of liver transplantation. It is important to prevent recurrence in cases of hepatitis B. Nucleos(t)ide analogs are the mainstay of HBV treatment before (in patients with decompensated cirrhosis) and after liver transplantation. After the introduction of direct-acting antivirals, the treatment of HCV has become considerably easy. In patients with advanced HCV-related cirrhosis, it is better to do transplantation first and treat them after liver transplantation. The sustained virological response rates have improved from 8 to 50% in the interferon era to 90% in the direct-acting antivirals era. In the current review, we discuss the treatment of HBV and HCV before and after liver transplantation.
doi_str_mv 10.1016/j.jceh.2023.09.008
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2902944920</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0973688323007089</els_id><sourcerecordid>2902944920</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-ae87e944afdd04e0d5d97f0aa1b0a095cfb654b2acab016bc18a4be7d307e0813</originalsourceid><addsrcrecordid>eNp9kM1OwzAQhC0EolXpC3BAOXJJ2NjOnwQHqIBWAtFD6dVy7E1xlCbFTivx9ri0cGQvK61mRjsfIZcxRDHE6U0d1Qo_IgqURVBEAPkJGVIas5DxhJ2SIRQZC9M8ZwMydq4GPylQDvScDFgOWcp5MiR3r7KVK9OugunDMpCtDqaTZTBrK1S96dpgbjH8Oc8714eN2aENFla2btPItr8gZ5VsHI6Pe0Tenx4Xk2n48vY8m9y_hIpB1ocS8wwLzmWlNXAEnegiq0DKuAQJRaKqMk14SaWSpe9WqjiXvMRMezdCHrMRuT7kbmz3uUXXi7VxChv_A3ZbJ2gB1OcXFLyUHqTKds5ZrMTGmrW0XyIGsScnarEnJ_bkBBTCk_Omq2P-tlyj_rP8cvKC24MAfcudQSucMtgq1MZ6UkJ35r_8b-mmfWk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2902944920</pqid></control><display><type>article</type><title>Managing HBV and HCV Infection Pre- and Post-liver Transplant</title><source>Alma/SFX Local Collection</source><creator>Kumar, Naveen ; Choudhary, Narendra S.</creator><creatorcontrib>Kumar, Naveen ; Choudhary, Narendra S.</creatorcontrib><description>Hepatitis B and C are common causes of end-stage liver disease and etiologies of liver transplantation. It is important to prevent recurrence in cases of hepatitis B. Nucleos(t)ide analogs are the mainstay of HBV treatment before (in patients with decompensated cirrhosis) and after liver transplantation. After the introduction of direct-acting antivirals, the treatment of HCV has become considerably easy. In patients with advanced HCV-related cirrhosis, it is better to do transplantation first and treat them after liver transplantation. The sustained virological response rates have improved from 8 to 50% in the interferon era to 90% in the direct-acting antivirals era. In the current review, we discuss the treatment of HBV and HCV before and after liver transplantation.</description><identifier>ISSN: 0973-6883</identifier><identifier>EISSN: 2213-3453</identifier><identifier>DOI: 10.1016/j.jceh.2023.09.008</identifier><identifier>PMID: 38076445</identifier><language>eng</language><publisher>India: Elsevier B.V</publisher><subject>decompensated cirrhosis recurrence ; delisting ; direct-acting antivirals</subject><ispartof>Journal of clinical and experimental hepatology, 2024-03, Vol.14 (2), p.101287-101287, Article 101287</ispartof><rights>2023 Indian National Association for Study of the Liver</rights><rights>2023 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-ae87e944afdd04e0d5d97f0aa1b0a095cfb654b2acab016bc18a4be7d307e0813</cites><orcidid>0000-0002-4387-0036</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38076445$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumar, Naveen</creatorcontrib><creatorcontrib>Choudhary, Narendra S.</creatorcontrib><title>Managing HBV and HCV Infection Pre- and Post-liver Transplant</title><title>Journal of clinical and experimental hepatology</title><addtitle>J Clin Exp Hepatol</addtitle><description>Hepatitis B and C are common causes of end-stage liver disease and etiologies of liver transplantation. It is important to prevent recurrence in cases of hepatitis B. Nucleos(t)ide analogs are the mainstay of HBV treatment before (in patients with decompensated cirrhosis) and after liver transplantation. After the introduction of direct-acting antivirals, the treatment of HCV has become considerably easy. In patients with advanced HCV-related cirrhosis, it is better to do transplantation first and treat them after liver transplantation. The sustained virological response rates have improved from 8 to 50% in the interferon era to 90% in the direct-acting antivirals era. In the current review, we discuss the treatment of HBV and HCV before and after liver transplantation.</description><subject>decompensated cirrhosis recurrence</subject><subject>delisting</subject><subject>direct-acting antivirals</subject><issn>0973-6883</issn><issn>2213-3453</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OwzAQhC0EolXpC3BAOXJJ2NjOnwQHqIBWAtFD6dVy7E1xlCbFTivx9ri0cGQvK61mRjsfIZcxRDHE6U0d1Qo_IgqURVBEAPkJGVIas5DxhJ2SIRQZC9M8ZwMydq4GPylQDvScDFgOWcp5MiR3r7KVK9OugunDMpCtDqaTZTBrK1S96dpgbjH8Oc8714eN2aENFla2btPItr8gZ5VsHI6Pe0Tenx4Xk2n48vY8m9y_hIpB1ocS8wwLzmWlNXAEnegiq0DKuAQJRaKqMk14SaWSpe9WqjiXvMRMezdCHrMRuT7kbmz3uUXXi7VxChv_A3ZbJ2gB1OcXFLyUHqTKds5ZrMTGmrW0XyIGsScnarEnJ_bkBBTCk_Omq2P-tlyj_rP8cvKC24MAfcudQSucMtgq1MZ6UkJ35r_8b-mmfWk</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Kumar, Naveen</creator><creator>Choudhary, Narendra S.</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4387-0036</orcidid></search><sort><creationdate>20240301</creationdate><title>Managing HBV and HCV Infection Pre- and Post-liver Transplant</title><author>Kumar, Naveen ; Choudhary, Narendra S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-ae87e944afdd04e0d5d97f0aa1b0a095cfb654b2acab016bc18a4be7d307e0813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>decompensated cirrhosis recurrence</topic><topic>delisting</topic><topic>direct-acting antivirals</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumar, Naveen</creatorcontrib><creatorcontrib>Choudhary, Narendra S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical and experimental hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumar, Naveen</au><au>Choudhary, Narendra S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Managing HBV and HCV Infection Pre- and Post-liver Transplant</atitle><jtitle>Journal of clinical and experimental hepatology</jtitle><addtitle>J Clin Exp Hepatol</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>14</volume><issue>2</issue><spage>101287</spage><epage>101287</epage><pages>101287-101287</pages><artnum>101287</artnum><issn>0973-6883</issn><eissn>2213-3453</eissn><abstract>Hepatitis B and C are common causes of end-stage liver disease and etiologies of liver transplantation. It is important to prevent recurrence in cases of hepatitis B. Nucleos(t)ide analogs are the mainstay of HBV treatment before (in patients with decompensated cirrhosis) and after liver transplantation. After the introduction of direct-acting antivirals, the treatment of HCV has become considerably easy. In patients with advanced HCV-related cirrhosis, it is better to do transplantation first and treat them after liver transplantation. The sustained virological response rates have improved from 8 to 50% in the interferon era to 90% in the direct-acting antivirals era. In the current review, we discuss the treatment of HBV and HCV before and after liver transplantation.</abstract><cop>India</cop><pub>Elsevier B.V</pub><pmid>38076445</pmid><doi>10.1016/j.jceh.2023.09.008</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-4387-0036</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0973-6883
ispartof Journal of clinical and experimental hepatology, 2024-03, Vol.14 (2), p.101287-101287, Article 101287
issn 0973-6883
2213-3453
language eng
recordid cdi_proquest_miscellaneous_2902944920
source Alma/SFX Local Collection
subjects decompensated cirrhosis recurrence
delisting
direct-acting antivirals
title Managing HBV and HCV Infection Pre- and Post-liver Transplant
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T14%3A23%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Managing%20HBV%20and%20HCV%20Infection%20Pre-%20and%20Post-liver%20Transplant&rft.jtitle=Journal%20of%20clinical%20and%20experimental%20hepatology&rft.au=Kumar,%20Naveen&rft.date=2024-03-01&rft.volume=14&rft.issue=2&rft.spage=101287&rft.epage=101287&rft.pages=101287-101287&rft.artnum=101287&rft.issn=0973-6883&rft.eissn=2213-3453&rft_id=info:doi/10.1016/j.jceh.2023.09.008&rft_dat=%3Cproquest_cross%3E2902944920%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2902944920&rft_id=info:pmid/38076445&rft_els_id=S0973688323007089&rfr_iscdi=true